These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34182468)

  • 21. [Our experience with the treatment of Hodgkin lymphoma patients].
    Illés Á; Garai I; Miltényi Z
    Orv Hetil; 2023 Mar; 164(11):403-410. PubMed ID: 36934353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vanishing bile duct syndrome as a presentation of Hodgkin's lymphoma.
    Fatima I; Mahadevia H; Madhusudhana S; Shrestha A
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.
    Park SI; Shea TC; Olajide O; Reddy NM; Budde LE; Ghosh N; Deal AM; Noe JF; Ansell SM
    Blood Adv; 2020 Jun; 4(11):2548-2555. PubMed ID: 32516414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature.
    Pass AK; McLin VA; Rushton JR; Kearney DL; Hastings CA; Margolin JF
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):976-80. PubMed ID: 19131796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
    Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
    Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
    Phillips T; Migliaccio-Walle K; Yu KS; Bloudek B; Liu N; Fanale M; Burke JM
    Leuk Lymphoma; 2023 May; 64(5):1017-1025. PubMed ID: 37074674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
    Fujii H; Tsuji T; Sugitani M; Matsumoto Y; Yuba T; Tanaka S; Suga Y; Matsuyama A; Goda S; Omura A; Shiotsu S; Takumi C; Ono S; Hiraoka N
    Curr Probl Cancer; 2021 Dec; 45(6):100739. PubMed ID: 33810911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
    N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.
    Zhu C; Zhao Y; Yu F; Huang W; Wu W; He J; Cai Z; He D
    Front Immunol; 2021; 12():756583. PubMed ID: 35095839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
    Phillips T; Liu N; Bloudek B; Migliaccio-Walle K; Reynolds J; Burke JM
    J Manag Care Spec Pharm; 2023 Dec; 29(12):1312-1320. PubMed ID: 37921077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage III or IV classical Hodgkin lymphoma.
    Delea TE; Sharma A; Grossman A; Eichten C; Fenton K; Josephson N; Richhariya A; Moskowitz AJ
    J Med Econ; 2019 Feb; 22(2):117-130. PubMed ID: 30375910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vanishing Bile Duct Syndrome Secondary to Hodgkin Lymphoma in a Child.
    Palla Velangini S; Boddu D; Balakumar S; Premanand A; Kishore R; Mathew LG
    J Pediatr Hematol Oncol; 2022 Aug; 44(6):e945-e947. PubMed ID: 35796591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin's disease.
    Kömürcü S; Ozet A; Altundag MK; Arpaci F; Oztürk B; Celasun B; Tezcan Y
    Ann Hematol; 2002 Jan; 81(1):57-8. PubMed ID: 11807639
    [No Abstract]   [Full Text] [Related]  

  • 36. Vanishing bile duct syndrome and immunodeficiency preceding the diagnosis of Hodgkin lymphoma.
    Yeh P; Lokan J; Anantharajah A; Grigg A
    Intern Med J; 2014 Dec; 44(12a):1240-4. PubMed ID: 25442758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    Kumar A; Casulo C; Advani RH; Budde E; Barr PM; Batlevi CL; Caron P; Constine LS; Dandapani SV; Drill E; Drullinsky P; Friedberg JW; Grieve C; Hamilton A; Hamlin PA; Hoppe RT; Horwitz SM; Joseph A; Khan N; Laraque L; Matasar MJ; Moskowitz AJ; Noy A; Palomba ML; Schöder H; Straus DJ; Vemuri S; Yang J; Younes A; Zelenetz AD; Yahalom J; Moskowitz CH
    J Clin Oncol; 2021 Jul; 39(20):2257-2265. PubMed ID: 33909449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.
    Orellana-Noia VM; Isaac K; Malecek MK; Bartlett NL; Voorhees TJ; Grover NS; Hwang SR; Bennani NN; Hu R; Hill BT; Mou E; Advani RH; Carter J; David KA; Ballard HJ; Svoboda J; Churnetski MC; Magarelli G; Feldman TA; Cohen JB; Evens AM; Portell CA
    Blood Adv; 2021 Sep; 5(18):3623-3632. PubMed ID: 34448831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
    Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
    Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard therapies versus novel therapies in Hodgkin lymphoma.
    Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
    Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.